Table 1 Patient demographics and baseline characteristics
OTX-101 n = 1846 | CsA n = 2248 | LFT n = 3008 | |
|---|---|---|---|
Age at index date, years | |||
Mean ± SD | 60.6 ± 13.0 | 64.6 ± 11.9 | 62.4 ± 11.9 |
Median (IQR) | 62.0 (53.0, 71.0) | 66.0 (58.0, 74.0) | 63.0 (55.0, 72.0) |
Sex, n (%) | |||
Female | 1539 (83.4) | 1935 (86.1) | 2555 (84.9) |
Male | 307 (16.6) | 313 (13.9) | 453 (15.1) |
Geographic region, n (%) | |||
South | 656 (35.5) | 829 (36.9) | 1061 (35.3) |
Northeast | 477 (25.8) | 659 (29.3) | 945 (31.4) |
West | 425 (23.0) | 314 (14.0) | 418 (13.9) |
Midwest | 280 (15.2) | 445 (19.8) | 584 (19.4) |
DED diagnosis, n (%) | |||
Tear film insufficiency, unspecified | 1299 (70.4) | 1639 (72.9) | 2201 (73.2) |
Keratoconjunctivitis sicca | 570 (30.9) | 630 (28.0) | 778 (25.9) |
Sicca syndrome, Sjögren | 364 (19.7) | 371 (16.5) | 499 (16.6) |
Ocular pain | 114 (6.2) | 102 (4.5) | 144 (4.8) |
Exposure keratoconjunctivitis | 29 (1.6) | 21 (0.9) | 32 (1.1) |
Neurotrophic keratoconjunctivitis | 11 (0.6) | 11 (0.5) | 15 (0.5) |
Punctate keratitis | 3 (0.2) | 3 (0.1) | 2 (0.1) |
Conjunctival xerosis | 0 | 2 (0.1) | 3 (0.1) |
Year of first DED diagnosis, n (%) | |||
2019 | 723 (39.2) | 782 (34.8) | 1031 (34.3) |
2020 | 861 (46.6) | 1051 (46.8) | 1383 (46.0) |
2021 | 262 (14.2) | 415 (18.5) | 594 (19.7) |
Type of insurance plan, n (%) | |||
Medicare | 621 (33.6) | 1244 (55.3) | 1173 (39.0) |
Commercial | 603 (32.7) | 589 (26.2) | 766 (25.5) |
Medicaid | 232 (12.6) | 268 (11.9) | 316 (10.5) |
Employer | 155 (8.4) | 196 (8.7) | 394 (13.1) |
Other | 256 (13.9) | 338 (15.0) | 520 (17.3) |
Unknown | 183 (9.9) | 203 (9.0) | 413 (13.7) |
Year of index date, n (%) | |||
2020 | 1157 (62.7) | 1544 (68.7) | 1726 (57.4) |
2021 | 689 (37.3) | 704 (31.3) | 1282 (42.6) |
Follow-up period, months | |||
Mean ± SD | 6.8 ± 3.3 | 7.6 ± 3.5 | 6.8 ± 3.4 |
Median (IQR) | 6.9 (4.2, 9.3) | 7.8 (4.7, 10.5) | 6.4 (3.9, 9.6) |